23 September 2021Jurisdiction reportsNaomi Pearce

Strategies for generic/biosimilar market entry in Australia

The pharma/biopharma industry shouldn’t underestimate the importance of strategising to achieve early market entry for generics and biosimilars, says Naomi Pearce of Pearce IP.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at

More on this story

10 August 2021   Allowing an AI as an inventor could benefit the country’s pharma and drug discovery industries, say Richard Hamer, Lauren John and Alexandra Moloney of Allens.
11 March 2021   Australia has unveiled plans to expand the technologies in which international research and development collaboration will face increased scrutiny to protect the country’s IP.